Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society...
-
Upload
kristina-bavis -
Category
Documents
-
view
222 -
download
0
Transcript of Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society...
![Page 1: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/1.jpg)
Confidential
The Device Development Industry
December 4, 2010
North American Neuromodulation Society
14th Annual Meeting
Frank Fischer
President and CEO
NeuroPace, Inc.
![Page 2: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/2.jpg)
Confidential
DEVICE DEVELOPMENT HAPPENS IN STAGES
1STAGE : CONCEPT DEVELOPMENT
STAGE : TESTING IN ANIMALS2
STAGE : CLINICAL EVALUATION IN HUMANS3
![Page 3: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/3.jpg)
Confidential
DEVICE DEVELOPMENT HAPPENS IN STAGES
1STAGE : CONCEPT DEVELOPMENT
• Test and refine theory – translate to a therapeutic approach• Characterize and improve approach in a representative
bench system
• Easy to iterate• Bench & In Vitro testing -
minimal regulatory issues• Cost of failure is minimal
![Page 4: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/4.jpg)
Confidential
STAGE : TESTING IN ANIMALS
DEVICE DEVELOPMENT HAPPENS IN STAGES
2
• Iteration possible but at a cost• Testing requires compliance to
protocols• Failure results in greater loss of
financial resources and time
• Learn about the downsides - characterize side effects, adverse reactions, limitations, technical hurdles• Glean some insights into efficacy, if possible
![Page 5: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/5.jpg)
Confidential
STAGE : CLINICAL EVALUATION IN HUMANS
DEVICE DEVELOPMENT HAPPENS IN STAGES
3
• Iterating the concept can be much more difficult• Clinical evaluation requires IRB
and/or FDA approval• Failure in almost every case is
very costly
• Prove safety and efficacy of your approach• If any uncertainty, parse this stage into parts (e.g.,
feasibility and pivotal)
![Page 6: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/6.jpg)
Confidential
STAGES ONE AND TWO LAY THE FOUNDATION FOR COMMERCIAL SUCCESS
• Confirm your product concept is feasible and has no obvious safety issues
• Develop intellectual property
1
2
Goals of stages 1 and 2
![Page 7: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/7.jpg)
Confidential
STAGES ONE AND TWO CAN BE COMPLETED WITH ONLY BASIC RESOURCES AND MINIMAL FUNDING
1
2
• Basic engineering and prototyping skills
• Internet/ library
• Intellectual property support
• Minimal funding
Resources required
Typically available at your university!
![Page 8: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/8.jpg)
Confidential
READY TO BLAST OFF? A SPECTRUM OF OPTIONS EXIST FOR HUMAN EVALUATION
Use already marketed, FDA approved devices
“Boldly go where no one has gone before” – build fully custom devices or systems
Build semi-custom devices via partnership with OEM device firm(s)
STAGE : CLINICAL EVALUATION IN HUMANS3
![Page 9: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/9.jpg)
Confidential
EXAMPLE: FUNCTIONAL NEUROSCIENCE
November 2010
“Functional Neuromodulation Inc., a medical technology company, closed a $600,000 seed financing from Genesys Capital”
October 2010
• Used off-the-shelf Medtronic DBS System
• 6 patients with mild Alz disease; stimulate the fornix/ hypothalamus
• Surgery and stimulation well tolerated• Results were mixed but highly
encouraging
STAGE : CLINICAL EVALUATION IN HUMANS3
![Page 10: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/10.jpg)
Confidential
EXAMPLE: LEPTOS
• Began human trials using Cyberonics devices
• Learned that gradual stimulation ramping was important to acclimate patients to stimulation
• Partner with OEM device manufacturers to build semi-custom neurostimulators and leads
• Automatic stimulation ramping • Custom lead specific for nerve target
• Stimulation of splanchnic nerve for obesity
STAGE : CLINICAL EVALUATION IN HUMANS3
![Page 11: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/11.jpg)
Confidential
EXAMPLE: NEUROPACE
• Responsive stimulation for the treatment of epilepsy
• Early realization that a fully custom system was necessary
• Build multi-functional team to develop and test implantable responsive neurostimulator, leads, programmer, remote patient monitor, and patient data management system
• Develop protocols for clinical evaluation; secure IDE approval from FDA; conduct clinical evaluations
STAGE : CLINICAL EVALUATION IN HUMANS3
![Page 12: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/12.jpg)
Confidential
EXAMPLE: NEUROPACE
2000 20102005
Develop-ment
Clinical Evaluation
Implantable RNS
eRNS Study RNS System Feasibility study65 patients
RNS System Pivotal trial191 patients
Perform basic testing in hospital setting with external system
Evaluate implantable system for safety and secondarily, efficacy. Gather data and learn!
Evaluate implantable system for efficacy and safety.
External RNS
![Page 13: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/13.jpg)
Confidential
EXAMPLE: NEUROPACE
![Page 14: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/14.jpg)
Confidential
COMPARISON OF STAGE 3 OPTIONS REVEALS KEY DIFFERENCESRESOURCES AND EXPERTISE REQUIRED
In-house engineering
+ ++ +++
Device dev expertise
+ ++ +++
Financial efficiency
+++ ++ +
IP opportunity + ++ +++
![Page 15: Confidential The Device Development Industry December 4, 2010 North American Neuromodulation Society 14 th Annual Meeting Frank Fischer President and CEO.](https://reader034.fdocuments.net/reader034/viewer/2022051014/5518bdf455034638098b47e4/html5/thumbnails/15.jpg)
Confidential
CONCLUSION
• Don’t be afraid to get started• Fail quickly!• Iterate until your concept is ready for clinical
evaluation• You cannot over invest in this phase
• Product development can take many paths, but almost always can be accomplished